Watson's oxybutynin topical gel meets OAB endpoint

Watson (NYSE:WPI) said its oxybutynin topical gel met the primary endpoint of a significant reduction in incontinence episodes vs. placebo in a Phase III trial to treat overactive bladder (OAB). The d...